Cargando…

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis

Detalles Bibliográficos
Autores principales:	Fang, Wenfeng, Zhou, Huaqiang, Shen, Jiayi, Li, Jianwen, Zhang, Yaxiong, Hong, Shaodong, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046406/ https://www.ncbi.nlm.nih.gov/pubmed/33551066 http://dx.doi.org/10.1136/esmoopen-2019-000614

Ejemplares similares

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
por: Liu, Jiaqing, et al.
Publicado: (2020)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
por: Zhou, Yong, et al.
Publicado: (2022)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

How to use immune checkpoint inhibitor in ovarian cancer?
por: Park, Junsik, et al.
Publicado: (2019)

Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
por: van der Geest, Kornelis S M, et al.
Publicado: (2022)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

Research progress in immune checkpoint inhibitors for lung cancer in China
por: Gan, Jiadi, et al.
Publicado: (2021)

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
por: Shen, Jiayi, et al.
Publicado: (2021)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
por: Suzuki, Rika, et al.
Publicado: (2023)

Comment on ‘Toxicities associated with immune checkpoint inhibitors: A systematic study’
por: Hosseini, Mohammad-Salar, et al.
Publicado: (2023)

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Takimoto, Takayuki
Publicado: (2020)

Trends in incidence and associated risk factors of suicide mortality in patients with non‐small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2018)

Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
por: Ma, Yuxiang, et al.
Publicado: (2021)

Genetic Liability to Insomnia and Lung Cancer Risk: A Mendelian Randomization Analysis
por: Shen, Jiayi, et al.
Publicado: (2021)

Reply to Takimoto: Micronodular Pattern of Organizing Pneumonia or Hypersensitivity Pneumonia Induced by an Immune Checkpoint Inhibitor?
por: Yamasaki, Masahiro, et al.
Publicado: (2020)

Immune-related genetic prognostic index to predict prognosis and immune checkpoint inhibitor therapy efficiency in acute myeloid leukemia
por: Cao, Xunhong, et al.
Publicado: (2023)

Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Lin, Zhihuan, et al.
Publicado: (2020)

Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database
por: HUANG, Sifu, et al.
Publicado: (2021)

Gut Microbiota and Lung Cancer: A Mendelian Randomization Study
por: Zhou, Huaqiang, et al.
Publicado: (2020)

IL-34 and Immune Checkpoint Inhibitors Resistant through Macrophages: Pan-Cancer Overview
por: Safi, Mohammed, et al.
Publicado: (2023)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
por: Liang, Fei, et al.
Publicado: (2020)

Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature
por: Kang, Yan, et al.
Publicado: (2023)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
por: Liang, Wenhua, et al.
Publicado: (2014)

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’
por: Takada, K., et al.
Publicado: (2022)

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer
por: Chen, Chen, et al.
Publicado: (2021)

Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
por: Li, Wen-Qian, et al.
Publicado: (2020)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning
por: Polano, Maurizio, et al.
Publicado: (2019)

Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study
por: Liu, Jiaqing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gdnphup9gt204nfsjvqqa0rj8o